lopinavir-ritonavir drug combination (Kaletra)

10/01/2022 - "We hypothesized that ARVs other than lopinavir and ritonavir might be responsible for some protection against the progression of COVID-19. "
01/01/2020 - "Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19."
06/01/2021 - "The results indicated that Kaletra had the most highest effect on improvement following COVID-19."
06/01/2021 - "Kaletra with odds ratio of 31.960 had the most highest effect on recovery following COVID-19 (P = .043). "
01/01/2021 - "Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients."

03/01/2022 - "Three aluvia regimens were applied; starting on the day of infection (acute phase), 2-week PI (early chronic phase) and eight weeks PI (late chronic phase). "
09/28/2009 - "Lopinavir and ritonavir are co-formulated in Kaletra approved for the treatment of human immunodeficiency virus infection. "
03/01/2007 - "The posttransplant course was complicated by several infection episodes and one episode of acute cellular rejection grade 2. HAART consisted of Lamivudine, Stavudine, Lopinavir and Ritonavir. "
11/01/2020 - "The aim of the present study was to evaluate the efficacy of interferon (IFN) with or without lopinavir and ritonavir as antiviral therapeutic option for treating COVID-19 infection. "
01/01/2020 - "To assess the plasma concentrations of lopinavir and ritonavir in patients with severe COVID-19 infection and receiving lopinavir/ritonavir. "

01/01/2020 - "Recently, four large Randomized Controlled Trials (RCTs) have been performed in record time delivering reliable data: (1) the National Institutes of Health (NIH) RCT included 60 hospitals participating all over the world and showed the efficacy of remdesivir in reducing the recovery time in hospitalized adults with COVID-19 pneumonia; (2) three large RCTs already completed, for hydroxychloroquine, dexamethasone and Lopinavir and Ritonavir respectively. "
06/05/2020 - "Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial."
10/01/2020 - "Results & methodology: Here we present two successful cases of tocilizumab administration in two COVID-19 patients with prior administration of antiviral therapy (hydroxychloroquine, azithromycin, lopinavir and ritonavir) with adequate response and resolution of ARDS, septic shock and severe pneumonia within the first 72 h. "

10/02/2020 - "Based on high alternative allele frequencies in population and the functional effect of the variants, ABCB1 rs1045642 and rs2032582 could be relevant for reduced clearance of azithromycin, lopinavir and ritonavir drugs and UGT1A7 rs17868323 for hyperbilirubinemia in ritonavir treated COVID-19 patients in Serbian population. "

03/01/2005 - "The dermatitis started respectively 7 and 10 days after taking Kaletra, improved on withdrawal, and relapsed following its reintroduction. "